BOEHRINGER-INGELHEIM
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine athletes, the diagnosis may mean many months of treatment and rehabilitation with an unknown outcome, and potential for long term impact on their ability to perform.
Boehringer Ingelheim has now received approval in Europe for RenuTend™, the first product licensed to improve healing of tendon and suspensory ligament injuries in horses. RenuTend™ is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell® FORTE, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
“We are delighted to add RenuTend™ to our portfolio of stem cell products for horses, offering veterinarians a new therapeutic option for treating tendon and suspensory ligament injuries. This product demonstrates the company's commitment to bringing innovation to improve the lives of horses and the people who love them,” comments Liz Barrett, Head of Global Strategic Marketing, Equine at Boehringer Ingelheim. “RenuTend™ will allow more riders, owners and trainers to reimagine the dreams a tendon injury jeopardizes, by optimizing the possibilities for their horse to return to work with reduced potential for reinjury.”
Tendon and ligament lesions don’t always heal properly, as scar tissue can be less elastic than healthy tissue, and reinjury rates can be up to 80 percent. This can mean the end of a career for many horses. RenuTend™ is a targeted stem cell treatment with proven efficacy and repeatable results. It improves the quality of tendon healing by promoting parallel alignment of the right type of fibres and decreases the amount of scar tissue formed.
RenuTend™ will be available across the European Union. The approval for Great Britain is still pending.
Please click on the link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/animal-health/companion-animals/horses/stem-cell-therapy-tendon-and-ligament-injuries-horses
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release
The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove
Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 22:30:00 CET | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project
Doha Debates Hosts “In The Room: The Negotiators Podcast” Live at Doha Forum9.12.2025 18:09:00 CET | Press release
As the podcast enters its fifth season, global diplomacy and high-stakes negotiation take center stage. Qatar Foundation’s Doha Debates spotlighted the practice of high-stakes negotiation with a special live episode of its award-winning podcast with Foreign Policy, The Negotiators, at Doha Forum, following the launch of the podcast series’ fifth season on December 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209171106/en/ Doha Debates spotlighted the practice of high-stakes negotiation with a special live episode of its award-winning podcast with Foreign Policy, The Negotiators, at Doha Forum, following the launch of the podcast series’ fifth season on December 1. (Photo: AETOSWire) Held in collaboration with The Negotiators’ special partner for this season, the International Peace Institute (IPI), and Doha Debates’ longstanding production partner, Foreign Policy, the episode featured a compelling conversation betwee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom